alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 251–275 of 963 studies with an author at Harvard University (US) (page 11 of 39) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden

✓ Peer-reviewed alzhub usefulness score 62 out of 100. JAMA neurology 2017-12-01

The following 2 regions for tau burden were identified: the entorhinal cortex, which exhibits early signs of tauopathy, and the inferior temporal region, which is more closely associated with AD-related pathologic mechanisms. 4 key findings →

Design: cross-sectional Participants: 133 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Telemedicine and the rural dementia population: A systematic review

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Maturitas 2020-09-24

The testing conditions and the accessibility of telemedicine yield inconclusive results as to whether telemedicine can improve the management of dementia in geriatric individuals. 4 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Nature neuroscience 2019-01-14

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are associated with loss of nuclear transactive response DNA-binding protein 43 (TDP-43). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Neuropathology and applied neurobiology 2015-02-01

Hereditary frontotemporal dementia associated with mutations in the microtubule-associated protein tau gene (MAPT) is a protean disorder. 1 key finding →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A parameter-efficient deep learning approach to predict conversion from mild cognitive impairment to Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 62 out of 100. NeuroImage 2019-01-14

The most novel characteristics of our machine learning model compared to previous ones are the following: 1) our deep learning model is multi-tasking, in the sense that it jointly learns to simultaneously predict both MCI to AD conversion as well as AD vs. healthy controls classification, which facilitates relevant feature extraction for AD prognostication; 2) the neural network classifier employs fewer parameters than other deep learning architectures which significantly limits data-overfitting (we use ∼550,000 network parameters, which is orders of magnitude lower than other network designs); 3) both structural MRI images and their warp field characteristics, which quantify local volumetric changes in relation to the MRI template, were used as separate input streams to extract as much information as possible from the MRI data. 1 key finding →

Participants: 785 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Resting state EEG biomarkers of cognitive decline associated with Alzheimer's disease and mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 62 out of 100. PloS one 2021-02-05

Compared to age matched controls, in the AD group, we found increases in both spectral power and coherence at the slower frequencies (Delta, Theta). 5 key findings →

Participants: 26 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Circadian disturbances in Alzheimer's disease progression: a prospective observational cohort study of community-based older adults

✓ Peer-reviewed alzhub usefulness score 62 out of 100. The lancet. Healthy longevity 2020-11-12

We used Cox proportional hazards models and logistic regressions to assess whether circadian disturbances predict an increased risk of incident Alzheimer's dementia and conversion of mild cognitive impairment to Alzheimer's dementia. 3 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of orthostatic hypotension with incident dementia, stroke, and cognitive decline

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Neurology 2018-07-25

We analyzed data from 11,709 participants without a history of coronary heart disease or stroke who attended the baseline examination (1987-1989) of the prospective Atherosclerosis Risk in Communities (ARIC) study. 4 key findings →

Participants: 11,709 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of Poor Sleep Burden in Middle Age and Older Adults With Risk for Delirium During Hospitalization

✓ Peer-reviewed alzhub usefulness score 62 out of 100. The journals of gerontology. Series A, Biological sciences and medical sciences 2022-03-01

Delirium is a distressing neurocognitive disorder recently linked to sleep disturbances. 4 key findings →

Design: longitudinal study Participants: 818 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The Neutrophil to Lymphocyte Ratio Is Associated With the Risk of Subsequent Dementia in the Framingham Heart Study

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Frontiers in aging neuroscience 2021-11-30

The objective of this study was to investigate whether increased NLR in older adults is independently associated with the risk of subsequent dementia. 4 key findings →

Design: longitudinal study Participants: 1,648 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2017-02-28

Sensitive detection of cognitive decline over the course of preclinical Alzheimer's disease is critical as the field moves toward secondary prevention trials. 4 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Identification of White Matter Hyperintensities in Routine Emergency Department Visits Using Portable Bedside Magnetic Resonance Imaging

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Journal of the American Heart Association 2023-05-23

Portable, low‐field imaging could be useful for identifying moderate to severe WMHs. 4 key findings →

Design: prospective cohort Participants: 33 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Race and Ethnicity, Lifestyle, Diet, and Survival in Patients With Prostate Cancer

✓ Peer-reviewed alzhub usefulness score 62 out of 100. JAMA Network Open 2025-02-26

A total of 2603 men with nonmetastatic PCa (mean [SD] age, 69.6 [7.1] years) were followed up, and 1346 deaths were documented, including 356 (24.6%) from CVD and 197 (14.6%) from PCa. 5 key findings →

Design: cohort study Participants: 2,603 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Childhood Loneliness and Cognitive Decline and Dementia Risk in Middle-Aged and Older Adults

✓ Peer-reviewed alzhub usefulness score 62 out of 100. JAMA Network Open 2025-09-12

Among 13 592 participants (mean [SD] age, 58.34 [9.39] years; 7175 [52.8%] female), 6525 (48.0%) experienced possible childhood loneliness, and 565 (4.2%) reported childhood loneliness. 5 key findings →

Design: cohort study Participants: 592 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed